Enumerate, peace: I doubt anyone would disagree, to date, PYC management have expertly built a lack of credibility, brought on by wildly optimistic guidance, a decline in the momentum of PYCs business plan and (imo) a lack of people skills by the previous CEO. While the same management remained, namely Paul and Nick, there was always going to be a blocking factor to the re-establishment of the company’s credibility and the ability to progress partnership discussions.
I see the appointment of Richard Hopkins as CEO as a ‘look to the future move’ by PYCs leading investor and PYCs board. It allows PYC to break down the blocking factor and build credibility once more. It gives PYC an advantage in developing and maintaining pharma relations
Also, it has been a deliberate tactic to use Hopkins to deliver the presentations on the ‘Endosomal Escape Trap’and I see Hopkins needs to be in control of negotiations during the coming months. SoT
PYC Price at posting:
1.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)